시장보고서

상품코드

1820180

백신 위탁생산 시장 보고서 : 백신 유형별, 워크플로우별, 용도별, 지역별(2025-2033년)

Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2025-2033

발행일: 2025년 09월 | 리서치사:

IMARC | 페이지 정보: 영문 138 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 백신 위탁생산 시장 규모는 2024년 30억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 63억 달러에 달할 것으로 예상하며, 2025-2033년 연평균 성장률(CAGR)은 8.45%를 보일 것으로 예측했습니다.

백신 위탁생산은 백신의 대량 생산을 위탁생산기관(CMO)에 위탁하는 것을 말합니다. CMO는 제제화 전 작업, 제제 개발, 제법 개발, 안정성 시험, 전임상 활동, 등록 배치, 상업 생산 등 다양한 서비스를 제공합니다. 이와는 별도로, 제약회사의 생산 체인을 확장하기 위한 전문 지식과 혁신적인 기술도 제공합니다. 현재 개발 비용 절감과 복잡한 제조 프로토콜을 이유로 백신 제조 업무의 아웃소싱에 대한 수요가 전 세계적으로 증가하고 있습니다.

백신 접종은 동물뿐만 아니라 인간의 건강 증진에도 매우 중요한 역할을 하고 있습니다. 항생제의 필요성을 줄이고 질병을 예방합니다. 백신 접종에 대한 인식이 높아지고 심각한 질병과 감염으로부터 자신을 보호할 수 있는 많은 이점이 예방접종 프로그램 및 예방접종에 대한 수요를 불러일으키고 있습니다. 이는 제조에 필요한 자본의 복잡성에 대한 이해와 함께 주요 제약회사들이 백신 제조를 아웃소싱으로 전환하고 있습니다. 이와는 별도로 저자원 국가들의 백신 제조를 위한 장비와 숙련된 인력의 부족도 세계 백신 위탁생산 시장의 성장에 기여하고 있습니다. 또한, EB66, GPEx와 같은 발현 시스템 및 세포배양 배지 플랫폼의 도입 등 기술 발전이 시장 성장을 뒷받침하고 있습니다. 또한, 많은 국가에서 코로나바이러스 감염증(COVID-19) 확진자가 우려할 만큼 증가함에 따라 백신 개발 기업들은 CMO와 아웃소싱 계약을 맺기 시작했습니다. 이는 시장 성장에 유리한 전망을 낳고 있습니다.

본 보고서에서 다룬 주요 질문

백신 위탁생산 시장 규모는?
백신 위탁생산 시장의 향후 전망은?
백신 위탁생산 시장을 이끄는 주요 요인은 무엇인가?
세계 백신 위탁생산 시장의 주요 기업은?

시장 구조
주요 기업
주요 기업 개요
- Ajinomoto Co. Inc.
- Albany Molecular Research Inc
- Catalent Inc
- Cobra Biologics Limited(Charles River Laboratories International Inc.)
- Cytovance Biologics Inc.(Hepalink USA Inc.)
- Fujifilm Holdings Corporation
- ICON plc
- IDT Biologika GmbH
- Lonza Group AG
- Merck KGaA
- Pharmaceutical Product Development LLC
- PRA Health Sciences Inc.

KSM

The global vaccine contract manufacturing market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.3 Billion by 2033, exhibiting a growth rate (CAGR) of 8.45% during 2025-2033.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

Breakup by Vaccine Type:

Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based

Breakup by Workflow:

Downstream
- Fill and Finish Operations
- Analytical and QC Studies
- Packaging
Upstream
- Mammalian Expression Systems
- Bacterial Expression Systems
- Yeast Expression Systems
- Baculovirus/Insect Expression Systems
- Others

Breakup by Application:

Human Use
Veterinary

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report

1.How big is the vaccine contract manufacturing market?
2.What is the future outlook of vaccine contract manufacturing market?
3.What are the key factors driving the vaccine contract manufacturing market?
4.Which are the leading companies in the global vaccine contract manufacturing market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Vaccine Type

6.1 Attenuated
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Inactivated
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Subunit-based
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Toxoid-based
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 DNA-based
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Workflow

7.1 Downstream
- 7.1.1 Market Trends
- 7.1.2 Key Segments
  - 7.1.2.1 Fill and Finish Operations
  - 7.1.2.2 Analytical and QC studies
  - 7.1.2.3 Packaging
- 7.1.3 Market Forecast
7.2 Upstream
- 7.2.1 Market Trends
- 7.2.2 Key Segments
  - 7.2.2.1 Mammalian Expression Systems
  - 7.2.2.2 Bacterial Expression Systems
  - 7.2.2.3 Yeast Expression Systems
  - 7.2.2.4 Baculovirus/Insect Expression Systems
  - 7.2.2.5 Others
- 7.2.3 Market Forecast

8 Market Breakup by Application

8.1 Human Use
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Veterinary
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Ajinomoto Co. Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Albany Molecular Research Inc
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 SWOT Analysis
- 14.3.3 Catalent Inc
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Fujifilm Holdings Corporation
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 ICON plc
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 IDT Biologika GmbH
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
- 14.3.9 Lonza Group AG
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Merck KGaA
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Pharmaceutical Product Development LLC
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 PRA Health Sciences Inc.
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials

백신 위탁생산 시장 보고서 : 백신 유형별, 워크플로우별, 용도별, 지역별(2025-2033년)

Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2025-2033

본 보고서에서 다룬 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 백신 위탁생산 시장

제6장 시장 내역 : 백신 유형별

제7장 시장 내역 : 워크플로우별

제8장 시장 내역 : 용도별

제9장 시장 내역 : 지역별

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도